IQVIA, Veeva Announce Long-term Clinical & Commercial Partnerships

IQVIA and Veeva Systems announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings from Veeva and IQVIA.

The global partnerships make it easy for customers to work with IQVIA and Veeva in Commercial and Clinical areas. 

The companies have established master data and software third-party access (TPA) agreements that allow IQVIA or Veeva data to be used with each other’s software or services in customer instances, including the use of IQVIA data in Veeva Network for master data management (MDM), Veeva Nitro for analytics, and Veeva AI. 

In addition to the use of Veeva data in IQVIA’s commercial products and services, IQVIA has also joined the Veeva Technology, AI, and Services Partner Programs to support customer integrations between Veeva software and IQVIA Analytics, IQVIA Information Management (including MDM), IQVIA Agentic AI, and IQVIA Commercial Orchestration offerings. 

IQVIA has also joined Veeva’s CRO Clinical Data Partner program and can leverage the Veeva Clinical Suite to execute clinical trials using Veeva software products, including study builds with Veeva EDC. 

With this partnership, customers will benefit from IQVIA’s clinical data management, clinical technology solutions, and EDC programming expertise with Veeva software to accelerate database builds, study locks, and data delivery.

“IQVIA and Veeva’s partnerships bring together best-in-class capabilities in information, AI, technology, and services for our shared clients,” said Ari Bousbib, chairman and CEO of IQVIA. “This will enable IQVIA customers on Veeva platforms to accelerate clinical development, bring treatments to market more efficiently, and improve access to innovations for patients.”